Suppr超能文献

微血管性心绞痛中血管生成因子水平升高。

Increased levels of angiogenic factors in microvascular angina.

作者信息

Asl Elmira Roshani, Rasmi Yousef, Khadem-Ansari Mohammad-Hasan, Seyed-Mohammadzad MirHossein, Rostamzadeh Alireza, Ghaffari Fereshteh, Mokarizadeh Narmin

机构信息

Department of Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.

Cellular and Molecular Research Center, Urmia University of Medical Sciences, Urmia, Iran.

出版信息

Med Pharm Rep. 2019 Jan;92(1):31-35. doi: 10.15386/cjmed-1101. Epub 2019 Jan 15.

Abstract

BACKGROUND

Recent studies have suggested that angiogenic factors may affect vascular endothelial integrity. On the other hand, endothelial dysfunction is the main pathological mechanism in microvascular angina (MVA) or cardiac syndrome X. Therefore, we aimed to determine the levels of angiogenic factors in MVA patients. In addition, we investigated the effects of metoprolol, as a beta blocker agent, on the serum levels of these factors.

METHODS

Thirty patients with MVA (17 female/13 male; mean age: 55.53±9.18 years) and twenty healthy controls (14 female/6 male; mean age: 51.40±9.16 years) were enrolled.The serum amounts of angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2) and tyrosine kinase-2 receptor (Tie-2) were measured in healthy controls, MVA patients at baseline and after metoprolol therapy (25 mg for one month) by enzyme-linked immunosorbent assay.

RESULTS

The levels of Ang-2 and Tie-2 were significantly higher in MVA patients at baseline in comparison with controls (Ang-2: 277.02±186.08 vs.164.46±49.83 ng/l, P=0.011; Tie-2: 28.97±18.85 vs. 14.90±4.05 ng/ml, P=0.002; respectively). But this difference in the Ang-1 levels was not significant (P=0.829). Additionally, the levels of angiogenic factors in MVA patients after metoprolol therapy were not significantly changed in comparison with the baseline status (P>0.05).

CONCLUSION

Our results considered a possible role for angiogenic factors in the pathophysiology of MVA, which need further investigation for elucidation. In addition, this study has not showed an effective role for metoprolol in changing the angiogenic factors levels as a therapeutic agent in MVA.

摘要

背景

近期研究表明血管生成因子可能影响血管内皮完整性。另一方面,内皮功能障碍是微血管性心绞痛(MVA)或心脏综合征X的主要病理机制。因此,我们旨在测定MVA患者血管生成因子的水平。此外,我们研究了作为β受体阻滞剂的美托洛尔对这些因子血清水平的影响。

方法

纳入30例MVA患者(17例女性/13例男性;平均年龄:55.53±9.18岁)和20例健康对照者(14例女性/6例男性;平均年龄:51.40±9.16岁)。通过酶联免疫吸附测定法测量健康对照者、MVA患者基线时以及美托洛尔治疗(25mg,持续1个月)后的血清血管生成素-1(Ang-1)、血管生成素-2(Ang-2)和酪氨酸激酶-2受体(Tie-2)的含量。

结果

与对照组相比,MVA患者基线时Ang-2和Tie-2水平显著更高(Ang-2:277.02±186.08 vs.164.46±49.83 ng/l,P = 0.011;Tie-2:28.97±18.85 vs. 14.90±4.05 ng/ml,P = 0.002)。但Ang-1水平的差异不显著(P = 0.829)。此外,与基线状态相比,美托洛尔治疗后MVA患者血管生成因子水平无显著变化(P>0.05)。

结论

我们的结果认为血管生成因子在MVA病理生理学中可能起作用,这需要进一步研究以阐明。此外,本研究未显示美托洛尔作为MVA治疗药物在改变血管生成因子水平方面的有效作用。

相似文献

1
Increased levels of angiogenic factors in microvascular angina.微血管性心绞痛中血管生成因子水平升高。
Med Pharm Rep. 2019 Jan;92(1):31-35. doi: 10.15386/cjmed-1101. Epub 2019 Jan 15.

引用本文的文献

1
Circulating Biomarkers in Coronary Microvascular Dysfunction.循环生物标志物与冠状动脉微血管功能障碍
J Am Heart Assoc. 2023 Jun 20;12(12):e029341. doi: 10.1161/JAHA.122.029341. Epub 2023 Jun 10.

本文引用的文献

2
Therapeutic targeting of the angiopoietin-TIE pathway.治疗性靶向血管生成素-TIE 通路。
Nat Rev Drug Discov. 2017 Sep;16(9):635-661. doi: 10.1038/nrd.2016.278. Epub 2017 May 19.
9
Cardiac Syndrome X: Update.心脏X综合征:最新进展
Heart Fail Clin. 2016 Jan;12(1):141-56. doi: 10.1016/j.hfc.2015.08.012.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验